Literature DB >> 26514685

Industry-academia collaborations for biomarkers.

Khusru Asadullah1,2, Andreas Busch1, Matthias Gottwald1, Petra Reinke2, Lilla Landeck2,3.   

Abstract

Several types of collaboration are being pursued to identify, validate and apply new biomarkers. Here, we highlight examples of such initiatives and discuss the challenges, approaches to address these challenges and key factors for success.

Mesh：

Substances：

Year:  2015        PMID： 26514685     DOI： 10.1038/nrd4727

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


  5 in total

1.  Crowdsourced analysis of clinical trial data to predict amyotrophic lateral sclerosis progression.

Authors:  Robert Küffner; Neta Zach; Raquel Norel; Johann Hawe; David Schoenfeld; Liuxia Wang; Guang Li; Lilly Fang; Lester Mackey; Orla Hardiman; Merit Cudkowicz; Alexander Sherman; Gokhan Ertaylan; Moritz Grosse-Wentrup; Torsten Hothorn; Jules van Ligtenberg; Jakob H Macke; Timm Meyer; Bernhard Schölkopf; Linh Tran; Rubio Vaughan; Gustavo Stolovitzky; Melanie L Leitner
Journal:  Nat Biotechnol       Date:  2014-11-02       Impact factor: 54.908

2.  Crowd sourcing in drug discovery.

Authors:  Monika Lessl; Justin S Bryans; Duncan Richards; Khusru Asadullah
Journal:  Nat Rev Drug Discov       Date:  2011-04       Impact factor: 84.694

3.  Grants4Targets: an open innovation initiative to foster drug discovery collaborations.

Authors:  Heidrun Dorsch; Alina Elisabeth Jurock; Stefanie Schoepe; Monika Lessl; Khusru Asadullah
Journal:  Nat Rev Drug Discov       Date:  2014-11-28       Impact factor: 84.694

4.  The predictive safety testing consortium and the coalition against major diseases.

Authors:  Diane Stephenson; John-Michael Sauer
Journal:  Nat Rev Drug Discov       Date:  2014-11       Impact factor: 84.694

5.  The biomarkers consortium.

Authors:  David Wholley
Journal:  Nat Rev Drug Discov       Date:  2014-11       Impact factor: 84.694
  5 in total
  4 in total

1.  Bridging the translational innovation gap through good biomarker practice.

Authors:  Alain J van Gool; Florence Bietrix; Eric Caldenhoven; Kurt Zatloukal; Andreas Scherer; Jan-Eric Litton; Gerrit Meijer; Niklas Blomberg; Andy Smith; Barend Mons; Jaap Heringa; Wim-Jan Koot; Martin J Smit; Marian Hajduch; Ton Rijnders; Anton Ussi
Journal:  Nat Rev Drug Discov       Date:  2017-04-28       Impact factor: 84.694

2.  Toward a Tiered Model to Share Clinical Trial Data and Samples in Precision Oncology.

Authors:  Stefanie Broes; Denis Lacombe; Michiel Verlinden; Isabelle Huys
Journal:  Front Med (Lausanne)       Date:  2018-01-29

3.  The price of progress: Funding and financing Alzheimer's disease drug development.

Authors:  Jeffrey Cummings; Carl Reiber; Parvesh Kumar
Journal:  Alzheimers Dement (N Y)       Date:  2018-06-13

4.  Circulating Tumor DNA Analysis: Clinical Implications for Colorectal Cancer Patients. A Systematic Review.

Authors:  Sander Bach; Nina R Sluiter; Jamie J Beagan; Joost M Mekke; Johannes C F Ket; Nicole C T van Grieken; Renske D M Steenbergen; Bauke Ylstra; Geert Kazemier; Jurriaan B Tuynman
Journal:  JNCI Cancer Spectr       Date:  2019-06-19
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.